top of page
The Professional Network for Healthcare Experts
Alteogen signs $365 million Hybrozyme licensing deal for subcutaneous biologic
The agreement gives an undisclosed global pharmaceutical company worldwide rights to use Alteogen’s ALT-B4 technology to develop and commercialise a subcutaneous formulation of an existing biologic.
nuaxia
Aug 72 min read
FDA proposes streamlined nonclinical safety studies for antibody-drug conjugates and other oncology biologics
The draft guidance could reduce reliance on animal studies for some oncology products while increasing the importance of analytical characterisation and weight-of-evidence approaches during development.
nuaxia
Aug 72 min read
bottom of page